Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/17/2024 | $7.00 | Buy | BTIG Research |
| 7/31/2024 | $7.00 → $5.00 | Neutral → Underweight | JP Morgan |
| 5/8/2024 | $11.50 → $9.00 | Overweight → Equal-Weight | Morgan Stanley |
| 1/17/2024 | Buy → Hold | Needham | |
| 1/5/2024 | Buy → Hold | Canaccord Genuity | |
| 7/24/2023 | $13.00 | Outperform → Neutral | Robert W. Baird |
| 4/19/2023 | Outperform | William Blair | |
| 12/9/2022 | $13.00 | Neutral | BofA Securities |
4 - Definitive Healthcare Corp. (0001861795) (Issuer)
4 - Definitive Healthcare Corp. (0001861795) (Issuer)
4 - Definitive Healthcare Corp. (0001861795) (Issuer)
10-Q - Definitive Healthcare Corp. (0001861795) (Filer)
8-K - Definitive Healthcare Corp. (0001861795) (Filer)
8-K - Definitive Healthcare Corp. (0001861795) (Filer)
FRAMINGHAM, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. ("Definitive Healthcare" or the "Company") (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced financial results for the quarter ended September 30, 2024. Third Quarter 2024 Financial Highlights: Revenue was $62.7 million, a decrease of 4% from $65.3 million in Q3 2023. Net Loss, inclusive of goodwill impairment charges of $228.2 million, was $(187.8) million, or (300%) of revenue, down 24% compared to $(248.7) million, inclusive of goodwill impairment charges of $287.4 million, or (381%) of revenue in Q3 2023.Adjusted Ne
FRAMINGHAM, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. ("Definitive Healthcare") (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced that it will report financial results for its third quarter ended September 30, 2024, on Thursday, November 7, 2024 after market close. The company will host a conference call and webcast at 5:00 PM (ET) / 2:00 PM (PT) to discuss the company's financial results. A live audio webcast of the event will be available on the Definitive Healthcare's Investor Relations website at https://ir.definitivehc.com/. A live dial-in will be available at 877-358-7298 (domestic) or +1-848-488-9244 (international).
FRAMINGHAM, Mass., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Definitive Healthcare (NASDAQ:DH), a leader in healthcare commercial intelligence, today announced the launch of Monocl Conferences. This solution is designed to enhance conference planning and participation for life science organizations by providing medical affairs, marketing, and conference planning teams with rich, contextualized conference data and access to the experts driving conference activities. By delivering a comprehensive overview of key conference insights—including information about presenters, timing, and locations of the most relevant scientific and medical updates—Monocl Conferences can help biopharma and medtech organ
FRAMINGHAM, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. ("Definitive Healthcare" or the "Company") (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced financial results for the quarter ended September 30, 2024. Third Quarter 2024 Financial Highlights: Revenue was $62.7 million, a decrease of 4% from $65.3 million in Q3 2023. Net Loss, inclusive of goodwill impairment charges of $228.2 million, was $(187.8) million, or (300%) of revenue, down 24% compared to $(248.7) million, inclusive of goodwill impairment charges of $287.4 million, or (381%) of revenue in Q3 2023.Adjusted Ne
FRAMINGHAM, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. ("Definitive Healthcare") (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced that it will report financial results for its third quarter ended September 30, 2024, on Thursday, November 7, 2024 after market close. The company will host a conference call and webcast at 5:00 PM (ET) / 2:00 PM (PT) to discuss the company's financial results. A live audio webcast of the event will be available on the Definitive Healthcare's Investor Relations website at https://ir.definitivehc.com/. A live dial-in will be available at 877-358-7298 (domestic) or +1-848-488-9244 (international).
FRAMINGHAM, Mass., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. ("Definitive Healthcare" or the "Company") (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced financial results for the quarter ended June 30, 2024. Second Quarter 2024 Financial Highlights: Revenue was $63.7 million, an increase of 5% from $61.0 million in Q2 2023. Net Loss, inclusive of goodwill impairment charges of $363.6 million, was $(306.2) million, or (480%) of revenue, up 2,538% compared to $(11.6) million, or (19%) of revenue in Q2 2023. Adjusted Net Income was $14.2 million, compared to $12.4 million in Q2 2023. Adjusted EBITDA was $20.9 million, up 21% from
SC 13G - Definitive Healthcare Corp. (0001861795) (Subject)
SC 13G - Definitive Healthcare Corp. (0001861795) (Subject)
SC 13G/A - Definitive Healthcare Corp. (0001861795) (Subject)
BTIG Research initiated coverage of Definitive Healthcare with a rating of Buy and set a new price target of $7.00
JP Morgan downgraded Definitive Healthcare from Neutral to Underweight and set a new price target of $5.00 from $7.00 previously
Morgan Stanley downgraded Definitive Healthcare from Overweight to Equal-Weight and set a new price target of $9.00 from $11.50 previously
FRAMINGHAM, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. ("Definitive Healthcare") (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced that its Board of Directors has appointed Kevin Coop as the Company's next Chief Executive Officer and as a member of the Board of Directors, each effective June 24, 2024. Mr. Coop succeeds Jason Krantz, founder and Executive Chairman, who has been serving as Interim CEO since January 2024. Mr. Krantz will continue to serve on the Board of Directors as Executive Chairman after the CEO transition. "Kevin is an outstanding leader. He has deep, hands-on experience with data-focused businesses and has a
Jim Emling, the CEO of Datassential and former long-time president of Milwaukee-based Zywave, has been appointed Executive Chair of the Board of Directors at VBA, the company announced today. "We are delighted to welcome Jim officially to VBA as the Executive Chair," said Michael Clayton, the company's President and CEO. "Jim and I have worked closely together over the last 3 months and his decades of experience scaling high growth software companies combined with his strong ties to the Milwaukee technology sector will be tremendous assets to VBA as we enter our next phase of growth." Emling has deep roots in the Milwaukee technology community. He was the founding CTO of Zywave and serv
FRAMINGHAM, Mass., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced that Carrie Lazorchak has been named Chief Revenue Officer, effective November 1, 2023. "I am thrilled to welcome Carrie Lazorchak to Definitive Healthcare as our new Chief Revenue Officer," said Robert Musslewhite, Chief Executive Officer of Definitive Healthcare. "Carrie is a fantastic fit for Definitive Healthcare. Her values and her deep belief in the power of humble collaboration make her a perfect match for our culture. Carrie brings a wealth of experience selling Software as a Service to both enterprise accounts and
Definitive Healthcare (NASDAQ:DH), a leader in healthcare commercial intelligence, today announced the launch of a redesigned mobile app for its popular View Suite platform. The new DH View Suite mobile app provides sales and marketing professionals with on-demand access to vital data and intelligence, maximizing their efficiency and success in the field.
Definitive Healthcare Corp. ("Definitive Healthcare") (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced that its Board of Directors has appointed Kevin Coop as the Company's next Chief Executive Officer and as a member of the Board of Directors, each effective June 24, 2024. Mr. Coop succeeds Jason Krantz, founder and Executive Chairman, who has been serving as Interim CEO since January 2024. Mr. Krantz will continue to serve on the Board of Directors as Executive Chairman after the CEO transition.
Deutsche Bank analyst George Hill maintains Definitive Healthcare (NASDAQ:DH) with a Hold and lowers the price target from $10 to $7.